| Dec'19 | Dec'18 | Dec'17 | ||||
|---|---|---|---|---|---|---|
Revenue | ||||||
Total revenue | ||||||
85,071 | 55,663 | 38,448 | ||||
Operating expenses | ||||||
Cost of revenue | ||||||
22,274 | 19,668 | 15,680 | ||||
Research and development | ||||||
70,705 | 39,157 | 31,995 | ||||
Sales and marketing | ||||||
38,453 | 24,486 | 16,765 | ||||
General and administrative | ||||||
30,332 | 20,409 | 15,949 | ||||
Amortization of intangible assets | ||||||
1,698 | 1,699 | 1,694 | ||||
Restructuring | ||||||
- | - | 840 | ||||
Total operating expenses | ||||||
163,462 | 105,419 | 82,923 | ||||
Loss from operations | ||||||
-78,391 | -49,756 | -44,475 | ||||
Interest and other income, net | ||||||
9,785 | 3,309 | 1,644 | ||||
Net loss | ||||||
-68,606 | -46,447 | -42,831 | ||||
Fair value adjustment to Series E-1 convertible preferred stock options | ||||||
964 | -102 | -135 | ||||
Net loss attributable to common shareholders | ||||||
-69,570 | -46,345 | -42,696 | ||||
Net loss per share attributable to common shareholders, basic and diluted | ||||||
-1.01 | -3.67 | -3.50 | ||||
Weighted-average shares used in computing net loss per share attributable to common shareholders, basic and diluted | ||||||
69,165 | 12,629 | 12,196 | ||||
Sequencing Revenue | ||||||
Total revenue | ||||||
43,519 | 32,978 | 22,759 | ||||
Development Revenue | ||||||
Total revenue | ||||||
41,552 | 22,685 | 15,689 | ||||